1. Home
  2. RGNX vs HELP Comparison

RGNX vs HELP Comparison

Compare RGNX & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo REGENXBIO Inc.

RGNX

REGENXBIO Inc.

HOLD

Current Price

$7.45

Market Cap

793.5M

Sector

Health Care

ML Signal

HOLD

Logo Cybin Inc. Common Stock

HELP

Cybin Inc. Common Stock

HOLD

Current Price

$11.12

Market Cap

862.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGNX
HELP
Founded
2008
2019
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
793.5M
862.2M
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
RGNX
HELP
Price
$7.45
$11.12
Analyst Decision
Buy
Strong Buy
Analyst Count
12
11
Target Price
$23.58
★ $41.40
AVG Volume (30 Days)
1.3M
★ 1.4M
Earning Date
11-09-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 18.08
N/A
EPS
N/A
★ N/A
Revenue
★ $10,393,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$23.50
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 126.48
N/A
52 Week Low
$5.46
$3.76
52 Week High
$16.19
$15.15

Technical Indicators

Market Signals
Indicator
RGNX
HELP
Relative Strength Index (RSI) 50.22 50.01
Support Level $6.96 $4.41
Resistance Level $8.31 $11.74
Average True Range (ATR) 0.43 0.89
MACD 0.06 0.06
Stochastic Oscillator 55.77 47.35

Price Performance

Historical Comparison
RGNX
HELP

About RGNX REGENXBIO Inc.

Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

Share on Social Networks: